Moran Sean F. 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Moran Sean F.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$30.00/sh+1,958$58,740→ 50,563 total - Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.12/sh−1,958$82,479→ 48,605 total - Exercise/Conversion
Options to purchase common stock
2024-06-18−1,958→ 0 totalExercise: $30.00Exp: 2024-10-22→ Common Stock (1,958 underlying) - Sale
Common Stock, par value $0.0001 per share
2024-06-14$49.87/sh−7,788$388,417→ 48,605 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-17$14.10/sh+6,730$94,893→ 55,335 total - Exercise/Conversion
Options to purchase common stock
2024-06-14−1,567→ 1,958 totalExercise: $30.00Exp: 2024-10-22→ Common Stock (1,567 underlying) - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$4.26/sh+7,788$33,177→ 56,393 total - Sale
Common Stock, par value $0.0001 per share
2024-06-17$46.77/sh−6,730$314,789→ 48,605 total - Sale
Common Stock, par value $0.0001 per share
2024-06-14$49.87/sh−1,567$78,152→ 48,605 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$30.00/sh+1,567$47,010→ 50,172 total - Exercise/Conversion
Options to purchase common stock
2024-06-14−7,788→ 23,367 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (7,788 underlying) - Exercise/Conversion
Options to purchase common stock
2024-06-17−6,730→ 11,217 totalExercise: $14.10From: 2023-02-01Exp: 2032-02-01→ Common Stock (6,730 underlying)
Footnotes (8)
- [F1]This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
- [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F6]The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.
- [F7]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
- [F8]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.